Axonics Modulation Technologies
Axonics Modulation Technologies, founded in 2012 and headquartered in Irvine, California, developed and commercialized implantable sacral neuromodulation devices for treating overactive bladder, urinary incontinence, and fecal incontinence, serving urologists and urogynecologists via direct hospital sales. Acquired by Boston Scientific in November 2024 for approximately $6.0 billion.
- Company typePrivate
- Founded2012
- HeadquartersIrvine, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Axonics Modulation Technologies does
Axonics Modulation Technologies is a medical device company founded in 2012 and headquartered in Irvine, California, specializing in the development and commercialization of implantable sacral neuromodulation (SNM) devices for the treatment of pelvic floor disorders. The company's core products target patients with chronic overactive bladder, urinary incontinence, fecal incontinence, and urinary retention who have failed conservative therapies such as medication and behavioral interventions. Axonics' proprietary technology delivers controlled electrical stimulation to the sacral nerve via an implanted pulse generator, leads, and remote control accessories, addressing a clinical niche within the broader neuromodulation space.
The company's business model is built on hardware sales of implantable SNM systems to hospitals, specialty clinics, and urology/urogynecology practices through a direct enterprise field sales force. Revenue is generated through initial device implantation procedures plus recurring sales of replacement components and accessories over multi-year device lifecycles. Axonics targeted medical specialists—primarily urologists, urogynecologists, and colorectal surgeons—who serve as both clinical decision-makers and implanting physicians. Marketing channels included medical conferences, peer-to-peer physician education, and clinical publications to drive adoption among key opinion leaders.
Following its initial public offering on NASDAQ under ticker AXNX, Axonics scaled commercially and executed the 2021 acquisition of Contura for approximately $200 million to expand its neuromodulation portfolio. In November 2024, Boston Scientific completed its acquisition of Axonics for approximately $6.0 billion, integrating the company's SNM technology and pelvic floor health products into Boston Scientific's Neuromodulation segment, which subsequently reported 15% organic sales growth with explicit contributions from the Axonics business.
Axonics Modulation Technologies firmographics
Firmographics- Name
- Axonics Modulation Technologies
- Legal name
- Axonics Inc.
- Website
- https://axonics.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Axonics Modulation Technologies, founded in 2012 and headquartered in Irvine, California, developed and commercialized implantable sacral neuromodulation devices for treating overactive bladder, urinary incontinence, and fecal incontinence, serving urologists and urogynecologists via direct hospital sales. Acquired by Boston Scientific in November 2024 for approximately $6.0 billion.
- Ownership category
- akta.pro rank
Axonics Modulation Technologies industry classification
Industry- Product category
- Sacral Neuromodulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industries
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE), Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)
Keywords
Where Axonics Modulation Technologies is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Axonics Modulation Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Implantable Neuromodulation Devices: Sale of sacral neuromodulation implantable devices for treating pelvic floor disorders. Revenue generated from device sales to hospitals and specialty clinics for implantation procedures.
- Device Accessories and Replacements: Revenue from accessories, replacement components, and ongoing patient follow-up products associated with the implanted neuromodulation systems.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
Axonics Modulation Technologies product offering
Product offeringCore offering
Axonics Modulation Technologies develops and manufactures implantable sacral neuromodulation (SNM) devices that deliver electrical stimulation to the sacral nerve to treat overactive bladder, urinary incontinence, and fecal incontinence. The company also sells accessories, replacement components, and patient follow-up products associated with its implanted neuromodulation systems.
Differentiator
Problem solved
Functional benefit
Products and services
- Sacral Neuromodulation (SNM) Implantable Devices
- Device Accessories and Replacements
Companies that use Axonics Modulation Technologies
Customer profileSegments3 records
Ideal customer profiles2 records
Axonics Modulation Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Axonics Modulation Technologies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Boston Scientific CorporationflagshipBoston Scientific completed the acquisition of Axonics Inc. in November 2024, integrating Axonics' sacral neuromodulation technology and pelvic floor health products into Boston Scientific's broader neuromodulation and pelvic health portfolio. The acquisition strengthened Boston Scientific's position as a key player in the pelvic floor health technology market.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Axonics Modulation Technologies competitors and assessment
Company assessmentDirect peers
- Medtronic: Medtronic markets InterStim, the leading sacral neuromodulation system for overactive bladder and incontinence, and is the dominant direct competitor to Axonics in the same SNM therapy category and same physician call point (urology/urogynecology).
- Nevro Corp: Nevro develops implantable spinal cord stimulation (HF10 therapy) systems for chronic pain, making it a direct peer in the implantable neuromodulation device category targeting physician specialists.
- Inspire Medical Systems: Inspire markets an implantable neurostimulation device for obstructive sleep apnea, making it a direct peer in the implantable neuromodulation device category targeting specialist physicians and hospital implanters.
- Laborie Medical Technologies: Laborie is a urology and pelvic health device company whose portfolio overlaps with Axonics' end market (urologists treating incontinence and pelvic floor disorders), making it a peer along the same physician call point.
Broad incumbents
- Boston Scientific Corporation: Parent company of Axonics following the November 2024 acquisition and a broad incumbent in neuromodulation (spinal cord stimulation, deep brain stimulation) and pelvic health; operates a wider portfolio that overlaps with Axonics' SNM franchise.
- Abbott: Abbott's Neuromodulation business (Proclaim family) operates in implantable neurostimulation (spinal cord and dorsal root ganglion stimulation) for chronic pain, overlapping broadly with the neuromodulation category Axonics operates in.
- Coloplast: Coloplast is a major player in continence care and pelvic health products (catheters, slings, bowel management), addressing the same patient population and physician call point as Axonics through adjacent, non-implant therapies.
Emerging players
- Nuvectra: Nuvectra developed the Algovita spinal cord stimulation system, an emerging player in implantable neuromodulation with partial overlap with Axonics in the broader neurostim device category.
- Cogentix Medical (now part of Laborie): Cogentix (now under Laborie) develops urology devices including Urgent PC percutaneous tibial nerve stimulation (PTNS), a non-implantable alternative therapy competing for the same refractory OAB patient population Axonics serves.
- Stimwave Technologies: Stimwave developed miniaturized, wirelessly powered peripheral nerve stimulation systems, representing an emerging neurostimulation peer with overlapping technology and therapeutic positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Axonics Modulation Technologies social profiles
Digital presenceAxonics Modulation Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Axonics Modulation Technologies leadership team
Management profileNumber of profiles
Profiles6 records
Axonics Modulation Technologies funding detail
Funding detailFunding overview
Funding rounds10 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Axonics Modulation Technologies M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Axonics Modulation Technologies
What does Axonics Modulation Technologies do?
Axonics Modulation Technologies develops and manufactures implantable sacral neuromodulation (SNM) devices that deliver electrical stimulation to the sacral nerve to treat overactive bladder, urinary incontinence, and fecal incontinence. The company also sells accessories, replacement components, and patient follow-up products associated with its implanted neuromodulation systems.
Is Axonics Modulation Technologies a public or private company?
Axonics Modulation Technologies is a private company. It is classified as corporate owned and is currently acquired.
When was Axonics Modulation Technologies founded?
Axonics Modulation Technologies was founded in 2012. It employs 501 to 1,000 people.
Where is Axonics Modulation Technologies based?
Axonics Modulation Technologies is headquartered in Irvine, United States, in the North America region.
How does Axonics Modulation Technologies make money?
Two revenue lines are on record. Implantable Neuromodulation Devices are the primary driver. The others are device Accessories and Replacements.
Who are Axonics Modulation Technologies's main competitors?
Direct peers on record are Medtronic, Nevro Corp, Inspire Medical Systems and Laborie Medical Technologies. Broad incumbents are Boston Scientific Corporation, Abbott and Coloplast. Emerging players are Nuvectra, Cogentix Medical (now part of Laborie) and Stimwave Technologies.
Does Axonics Modulation Technologies have an API?
No public API is recorded for Axonics Modulation Technologies.
What industry is Axonics Modulation Technologies in?
Axonics Modulation Technologies's product category is Sacral Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.